NasdaqGM - Nasdaq Real Time Price USD

Fate Therapeutics, Inc. (FATE)

Compare

1.0600

+0.1248

+(13.34%)

At close: 4:00:01 PM EDT

1.0500

-0.01

(-0.94%)

After hours: 6:30:02 PM EDT

Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 7 days ago

FATE
+13.34%
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2025 the Company granted restricted stock units (RSUs) representing 32,200 shares of its common stock to two newly-hired non-executive employees. The grants were approv

GlobeNewswire 9 days ago

FATE
+13.34%
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target

Last week, you might have seen that Fate Therapeutics, Inc. ( NASDAQ:FATE ) released its full-year result to the...

Simply Wall St. last month

FATE
+13.34%
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus

FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.

Zacks last month

FATE
+13.34%
OPHLY
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 29.55% and 46.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

FATE
+13.34%
Fate Therapeutics: Q4 Earnings Snapshot

On a per-share basis, the San Diego-based company said it had a loss of 44 cents. Losses, adjusted for asset impairment costs, came to 31 cents per share. The results topped Wall Street expectations.

Associated Press Finance last month

FATE
+13.34%
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE Completed Type D Meeting with FDA to Enable FT819 Off-the-Shelf CAR T-cell Dose Expansion in Additional B Cell-mediated Autoimmune Diseases First FT819 Off-the-Shelf CAR T-cell Patient Treated without Conditioning Chemotherapy as Add-on to Maintenance Therapy in SLE $307 Million in Cash, Cash Equivalents and Investments with Projected Operating Runway

GlobeNewswire last month

FATE
+13.34%
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 3, 2025 the Company granted restricted stock units (RSUs) representing 24,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved

GlobeNewswire last month

FATE
+13.34%
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

NVCR

FATE
+13.34%
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

FATE
+13.34%
GH
Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference, including a fireside chat at 1:30 PM ET on T

GlobeNewswire last month

FATE
+13.34%
We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 2 months ago

FATE
+13.34%
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 3 months ago

FATE
+13.34%
CLDX
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company de

GlobeNewswire 3 months ago

FATE
+13.34%
Fate Therapeutics makes Bob Valamehr president and CEO

The change comes as the company reaffirms its commitment to developing new off-the-shelf cellular immunotherapies.

Pharmaceutical Technology 4 months ago

FATE
+13.34%
Fate Therapeutics Announces Leadership Transition

Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (“Fate Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and aut

GlobeNewswire 4 months ago

FATE
+13.34%
Fate Therapeutics to Present at Upcoming December Investor Conferences

SAN DIEGO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences: Citi’s 2024 Global Healthcare Conference, including a panel discussion at 2:30 PM ET on Tuesday, Decembe

GlobeNewswire 4 months ago

FATE
+13.34%
Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results

Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results

PREMIUM
MT Newswires 4 months ago

FATE
+13.34%
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Patient Treated with Fludarabine-free Conditioning and Single-dose FT819; Favorable Safety Profile with No Grade ≥3 Adverse Events and No Events of CRS, ICANS, or GvHD Reconstituted B Cell Compartment Predominantly Consists of Naïve, Non-class Switched B Cells with Deep Depletion of Aberrant B Cells an

GlobeNewswire 4 months ago

FATE
+13.34%
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens without Conditioning Chemotherapy Initial Phase 1 Clinical Data in Relapsed / Refractory B-cell Lymphoma Show Favorable Safety Profile, Complete Responses, and Persistence of FT522 Live Cells Selective Targeting and Reduction of CD19+ B Cells Observed with Each FT522 Dose in Study’s First Low-dose Cohort without Conditioning Chemotherapy, Supporting Novel

GlobeNewswire 4 months ago

FATE
+13.34%

Performance Overview

Return	FATE	S&P 500 (^GSPC)
YTD	-35.76%	-8.81%
1-Year	-82.18%	+3.16%
3-Year	-97.04%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Fate Therapeutics, Inc. (FATE)

Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target

FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

Fate Therapeutics: Q4 Earnings Snapshot

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know

Fate Therapeutics to Present at Upcoming Investor Conferences

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Fate Therapeutics makes Bob Valamehr president and CEO

Fate Therapeutics Announces Leadership Transition

Fate Therapeutics to Present at Upcoming December Investor Conferences

Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

Performance Overview